PRAC

The HTA Project Group focuses on strengthening EANM’s contributions to EU Health Technology Assessment policy and implementation. It brings together experts to support policy engagement, knowledge exchange, and capacity building on HTA‑related topics relevant to nuclear medicine. Key activities include contributing to consultation processes, supporting educational initiatives, and liaising with scientific and professional stakeholders. The group helps position EANM as a trusted partner in HTA discussions at EU level.

Lead: Nadia Withofs 

Learn more here. 

The Cardiovascular Health Plan Project Group supports EANM’s engagement in the development of the EU Cardiovascular Health Plan. Its goal is to ensure that nuclear medicine is appropriately represented in EU‑level cardiovascular policy discussions. The group coordinates expert input, contributes to consultations and stakeholder dialogues, and supports the development of EANM advocacy and policy materials. It works in close collaboration with relevant EANM committees and external partners.

Learn more here. 

The ACT EU & Clinical Trials Project Group was established to support EANM’s engagement in the EU Accelerating Clinical Trials in the EU (ACT EU) initiative and the implementation of the Clinical Trials Regulation. Its objective is to address regulatory, methodological, and practical challenges affecting nuclear medicine clinical trials, particularly academic and investigator‑initiated studies. The group coordinates expert input, develops guidance and policy positions, and represents EANM in ACT EU‑related stakeholder platforms and focus groups. Through advocacy activities and evidence building, it aims to improve the feasibility, quality, and harmonisation of clinical trials in nuclear medicine across Europe.

Lead: Laura Evangelista 

The Regulatory Aspects Project Group brings together radiopharmacy and regulatory experts to support EANM’s engagement with EU pharmaceutical and radiopharmaceutical regulation. Initially established in the context of the EU pharmaceutical legislation revision, the group now focuses on monitoring and contributing to regulatory developments led by the European Medicines Agency (EMA) and the European Commission. Its activities include reviewing draft guidelines, preparing coordinated EANM feedback, and supporting dialogue with regulators on regulatory frameworks applicable to radiopharmaceuticals.

The National Advocacy Project Group will aim at strengthening coordination between EU‑level policy activities and national implementation across EANM National Member Societies. Its objective is to equip national representatives with the tools, knowledge, and networks needed to engage effectively in policy and regulatory discussions. The group will collect best practices, facilitates mutual learning, and supports feedback on the real‑world impact of EU legislation at national level. Through this work, it will reinforce alignment between EU priorities and national advocacy efforts.

Call for nomination open. 

• EANM is looking for 5–6 nominees from member societies, not necessarily current EANM National Delegates, but individuals with a strong connection to their society’s leadership and an interest in policy and regulatory affairs.

• EANM warmly invites national societies to confirm their interest in joining and to nominate a representative. We encourage broad geographical representation and particularly welcome applications from countries with upcoming Council of the EU Presidencies.

• We will kindly ask national societies to fill this form with their nomination by May 3.